Related Experiment Video
Updated: Jan 23, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
A driving test for oncogenic mutations
David E Heppner1, Tyler S Beyett1, Michael J Eck2
1From the Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115.
Abstract:
Activating mutations in protein kinases are a frequent cause of cancer, and selecting drugs that act on these oncogenic kinases can lead to effective therapies. Targeted or whole-genome sequencing of tumor samples can readily reveal the presence of mutations, but discerning previously uncharacterized activating "driver" mutations that will respond to drug treatment from much more abundant but inconsequential "passenger" mutations is problematic. Chakroborty et al. apply a screening approach that leverages error-prone PCR and a proliferating cell model to identify such gain-of-function mutants in the epidermal growth factor receptor (EGFR) kinase. The screen is validated by the identification of known cancer-promoting mutations and reveals a previously unappreciated oncogenic EGFR mutation, A702V, demonstrating its power for discovery of driver mutations.
Insights
Researchers developed a new screening method to identify cancer-driving mutations in the epidermal growth factor receptor (EGFR) kinase. This approach successfully found known mutations and a novel oncogenic EGFR mutation, A702V.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Activating mutations in protein kinases drive cancer development.
- Identifying oncogenic driver mutations is crucial for effective cancer therapy.
- Distinguishing driver mutations from passenger mutations is a significant challenge.
Purpose of the Study:
- To develop and validate a screening approach for identifying gain-of-function mutations in the epidermal growth factor receptor (EGFR) kinase.
- To discover previously uncharacterized oncogenic EGFR mutations that can be targeted by drugs.
Main Methods:
- Utilized an error-prone PCR-based screening strategy.
- Employed a proliferating cell model to assess kinase activity.
- Validated the screen by identifying known cancer-promoting EGFR mutations.
Main Results:
- The screening method successfully identified known activating EGFR mutations.
- A novel oncogenic EGFR mutation, A702V, was discovered.
- The approach demonstrated efficacy in discovering driver mutations.
Conclusions:
- The developed screening approach is powerful for identifying oncogenic driver mutations.
- This method can accelerate the discovery of new therapeutic targets in cancer.
- The identification of EGFR A702V highlights the potential of this screen for future cancer research.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms

